Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2018

01-08-2018 | Original Article

High isolation rate and multidrug resistance tendency of penicillin-susceptible group B Streptococcus with reduced ceftibuten susceptibility in Japan

Authors: Hirotsugu Banno, Kouji Kimura, Tomomi Seki, Wanchun Jin, Jun-ichi Wachino, Keiko Yamada, Noriyuki Nagano, Yoshichika Arakawa

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2018

Login to get access

Abstract

Group B Streptococcus (GBS) clinical isolates with reduced penicillin susceptibility (PRGBS) have emerged through acquisition of amino acid substitutions in penicillin-binding protein 2X (PBP2X). Moreover, we also reported the emergence of penicillin-susceptible GBS clinical isolates with reduced ceftibuten susceptibility (CTBr PSGBS) due to amino acid substitutions in PBPs. However, whether or not these amino acid substitutions are responsible for the reduced ceftibuten susceptibility (RCTBS) profile remains unclear. Furthermore, the rate of CTBr PSGBS isolation and their multidrug resistance tendency remain uncertain. Therefore, we collected 377 clinical GBS isolates from multiple regions in Japan between August 2013 and August 2015. These isolates were characterized by determining MICs and sequencing the pbp2x gene. The isolation rate of CTBr PSGBS was 7.2% (27/377). CTBr PSGBS isolate harbor two types of amino acid substitutions in PBP2X [(T394A type) and (I377V, G398A, Q412L, and H438H type)]. The relevance of the amino acid substitutions found to the RCTBS was confirmed with allelic exchange techniques. Allelic exchange recombinant clones acquired two types of amino acid substitutions in PBP2X showed RCTBS. Furthermore, total ratio of resistance and non-susceptibility to both macrolides and fluoroquinolones in CTBr PSGBS was 51.9% (14/27). The isolation rate of CTBr PSGBS is non-negligibly high and the CTBr PSGBS tends to exhibit resistance and non-susceptible profile to both macrolides and fluoroquinolones.
Appendix
Available only for authorised users
Literature
6.
go back to reference Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases NCfI, Respiratory Diseases CfDC, Prevention (2010) Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recomm Rep 59:1–36PubMed Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases NCfI, Respiratory Diseases CfDC, Prevention (2010) Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recomm Rep 59:1–36PubMed
7.
go back to reference Schuchat A (1998) Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 11:497–513 Schuchat A (1998) Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 11:497–513
8.
go back to reference Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A (2002) Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 51:1–22PubMed Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A (2002) Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 51:1–22PubMed
10.
go back to reference Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working G (2009) Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections. Antimicrob Agents Chemother 53:2650–2653. https://doi.org/10.1128/AAC.01716-08 CrossRefPubMedPubMedCentral Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working G (2009) Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections. Antimicrob Agents Chemother 53:2650–2653. https://​doi.​org/​10.​1128/​AAC.​01716-08 CrossRefPubMedPubMedCentral
14.
go back to reference Dahesh S, Hensler ME, Van Sorge NM, Gertz RE, Jr., Schrag S, Nizet V, Beall BW. (2008) Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 52:2915–2918. https://doi.org/10.1128/AAC.00461-08 Dahesh S, Hensler ME, Van Sorge NM, Gertz RE, Jr., Schrag S, Nizet V, Beall BW. (2008) Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 52:2915–2918. https://​doi.​org/​10.​1128/​AAC.​00461-08
15.
go back to reference Kimura K, Nagano N, Nagano Y, Suzuki S, Wachino J, Shibayama K, Arakawa Y (2013) High frequency of fluoroquinolone- and macrolide-resistant streptococci among clinically isolated group B streptococci with reduced penicillin susceptibility. J Antimicrob Chemother 68:539–542. https://doi.org/10.1093/jac/dks423 CrossRefPubMed Kimura K, Nagano N, Nagano Y, Suzuki S, Wachino J, Shibayama K, Arakawa Y (2013) High frequency of fluoroquinolone- and macrolide-resistant streptococci among clinically isolated group B streptococci with reduced penicillin susceptibility. J Antimicrob Chemother 68:539–542. https://​doi.​org/​10.​1093/​jac/​dks423 CrossRefPubMed
18.
go back to reference Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing, 20th ed. Clinical and Laboratory Standards Institute, Wayne, PA, p M100 Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing, 20th ed. Clinical and Laboratory Standards Institute, Wayne, PA, p M100
23.
go back to reference Metcalf BJ, Chochua S, Gertz RE Jr, Hawkins PA, Ricaldi J, Li Z, Walker H, Tran T, Rivers J, Mathis S, Jackson D, Glennen A, Lynfield R, McGee L, Beall B, Active Bacterial Core surveillance t (2017) Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA. Clin Microbiol Infect 23:574 e577–574 e514. https://doi.org/10.1016/j.cmi.2017.02.021 CrossRef Metcalf BJ, Chochua S, Gertz RE Jr, Hawkins PA, Ricaldi J, Li Z, Walker H, Tran T, Rivers J, Mathis S, Jackson D, Glennen A, Lynfield R, McGee L, Beall B, Active Bacterial Core surveillance t (2017) Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA. Clin Microbiol Infect 23:574 e577–574 e514. https://​doi.​org/​10.​1016/​j.​cmi.​2017.​02.​021 CrossRef
Metadata
Title
High isolation rate and multidrug resistance tendency of penicillin-susceptible group B Streptococcus with reduced ceftibuten susceptibility in Japan
Authors
Hirotsugu Banno
Kouji Kimura
Tomomi Seki
Wanchun Jin
Jun-ichi Wachino
Keiko Yamada
Noriyuki Nagano
Yoshichika Arakawa
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3278-7

Other articles of this Issue 8/2018

European Journal of Clinical Microbiology & Infectious Diseases 8/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.